June 15, 2017 / 4:05 PM / in 2 months

BRIEF-Ose Immunotherapeutics presents positive preclinical results for OSE-127

June 15 (Reuters) - OSE IMMUNOTHERAPEUTICS SA

* OSE IMMUNOTHERAPEUTICS PRESENTS POSITIVE PRECLINICAL RESULTS AND HUMAN EX VIVO DATA FOR OSE-127 (EFFI-7) TO SUPPORT NEXT CLINICAL APPLICATIONS IN INFLAMMATORY BOWEL DISEASES

* ‍OSE-127 BLOCKS PATHOLOGICAL HOMING OF HUMAN T LYMPHOCYTES TO INFLAMED COLON​

* ‍EX VIVO, OSE-127 REDUCES PRODUCTION OF GAMMA INTERFERON BY HUMAN PROINFLAMMATORY BOWEL T LYMPHOCYTES IN PATIENTS' BIOPSIES​

* ‍COMMUNICATION SHOWS EFFICACY RESULTS FOR OSE-127 IN VARIOUS PRECLINICAL ACUTE OR CHRONIC COLITIS MODELS AND EX VIVO HUMAN BIOPSIES​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below